+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: Implication for melanoma progression

Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: Implication for melanoma progression

Journal of Cutaneous Pathology 23(6): 495-505

The molecular events responsible for tumor progression in human cutaneous malignant melanoma remain unclear; however, critical to the process is the dysregulated proliferation of tumor cells and the development of new vascular channels which allow further growth and dissemination. Connective tissue mast cells (MC) have been implicated in tumor progression because they concentrate around tumors (including melanomas) prior to the formation of new blood vessels, and because they contain many chemical mediators, including basic fibroblast growth factor (bFGF), known to have mitogenic and angiogenic effects. Several MC chemotactic and mitogenic factors have been described including interleukin-3 (IL-3). In order to determine whether there is a differential expression of this MC chemotactic/mitogenic factor with tumor progression in vivo, we evaluated by immunohistochemistry 85 melanocytic lesions including primary invasive malignant melanoma (PIMM), melanoma in situ (MMIS), and ordinary intradermal benign melanocytic nevi (BMN) for expression of IL-3. Nucleic acid in situ hybridization also was used to evaluate the melanocytic lesions for IL-3-specific mRNA transcripts. Intracellular IL-3 protein was detected in 29/33 (88%) PIMM and 15/25 (60%) MMIS, but was not detected in any (0/27; 0%) BMN (p lt 0.0001). IL-3-specific mRNA transcripts were present in 3/4 PIMM and 2/10 MMIS in which IL-3 protein was not identified, but were not detected in any BMN. IL-3 mRNA or protein was not detected in normal melanocytes present in the perilesional epidermis of any of the specimens studied. Immunohistochemistry also was used to confirm the presence of IL-3-alpha-specific receptors on human cutaneous MC. As demonstrated by others, a significantly increased number of MC was present in the perilesional stroma of PIMM and MMIS vis a vis BMN (p lt 0.0001). The results suggest that melanoma cells may attract MC in vivo by producing MC chemotactic/mitogenic factors such as IL-3. The recruitment of MC and the subsequent release of their potent mitogenic and angiogenic factors such as bFGF may thus represent a tumor-host interaction which favors tumor progression.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 008664565

Download citation: RISBibTeXText

PMID: 9001979

Related references

Expression of the mast cell growth factors interleukin 4 and stem cell factor in malignant melanoma correlates with increased numbers of mast cells in the peritumoral stroma. Modern Pathology 9(1): 45A, 1996

Preferential expression of interleukin-12 or interleukin-4 by murine bone marrow mast cells derived in mast cell growth factor or interleukin-3. European Journal of Immunology 24(4): 822-826, 1994

The early growth response factor-1 is involved in stem cell factor (SCF)-induced interleukin 13 production by mast cells, but is dispensable for SCF-dependent mast cell growth. Journal of Biological Chemistry 282(31): 22573-22581, 2007

Differential expression of mast cell growth factor receptor (c-kit) by peritoneal connective tissue-type mast cells and tissue culture-derived mast cells. Journal of Leukocyte Biology 55(5): 596-602, 1994

Expression of mast cell proteases correlates with mast cell maturation and angiogenesis during tumor progression. Plos One 7(7): E40790-E40790, 2013

BCL-2 and mast cell survival BCL-2 is overexpressed in a growth factor-independent mouse mast cell line but mast cells develop in BCL-2 null mice. FASEB Journal 8(4-5): A742, 1994

Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma. Blood 123(12): 1836-1849, 2014

Increased Number of Mast Cells in Atherosclerotic Lesions Correlates with the Presence of Myeloid but not Plasmacytoid Dendritic Cells as well as Pro-inflammatory T Cells. Clinical Laboratory 62(12): 2293-2303, 2017

Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. European Journal of Cancer 39(5): 666-674, March, 2003

Interleukin-3 and stem cell factor modulate cell cycle regulatory factors in mast cells: Negative regulation of p27Kip1 in proliferation of mast cells induced by interleukin-3 but not stem cell factor. Experimental Hematology (Charlottesville) 29(7): 803-811, July, 2001

Expression of receptors for interleukin 3 interleukin 6 and mast cell growth factor on cd34 positive hemopoietic cells in humans and rhesus monkeys. Experimental Hematology (Charlottesville) 20(6): 743, 1992

Gene expression and regulation of nerve growth factor in atopic dermatitis mast cells and the human mast cell line-1. Journal of Neuroimmunology 161(1-2): 87-92, 2005

Characterization of a T-cell-derived mast cell costimulatory activity (MCA) that acts synergistically with interleukin 3 and interleukin 4 on the growth of murine mast cells. Cytokine 2(6): 407-415, 1990

Interleukin (IL)-10 inhibits RANTES-, tumour necrosis factor (TNF)- and nerve growth factor (NGF)-induced mast cell migratory response but is not a mast cell chemoattractant. Immunology Letters 123(1): 46-51, 2009

Human testicular mast cells contain tryptase: Increased mast cell number and altered distribution in the testes of infertile men. Fertility & Sterility 74(2): 239-244, August, 2000